Research programme: botulinum toxin therapies - EpiVax

Drug Profile

Research programme: botulinum toxin therapies - EpiVax

Alternative Names: DeFT™; Deimmunised Botox

Latest Information Update: 24 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiVax
  • Class
  • Mechanism of Action Acetylcholine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dystonia

Most Recent Events

  • 24 Jul 2016 Preclinical development is ongoing in USA (
  • 26 Oct 2015 EpiVax and Ipsen collaborate to develop next generation botulinum neurotoxin and Targeted Secretion Inhibitor therapeutics
  • 09 Mar 2007 Preclinical trials in Dystonia in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top